Current role
Biotechnology · Healthcare
CEO, Board Member
2026-08-14–present
Joshua Pinto
Equibles does not estimate personal net worth.
Get an email with a short summary when Neumora Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get NMRA alertsAbout Joshua Pinto
Joshua Pinto is recorded as CEO and Board Member at Neumora Therapeutics, Inc. (NMRA) since August 14, 2026. Neumora Therapeutics, Inc. reported in an 8-K filed August 14, 2026 that Joshua Pinto was appointed Class III director, effective August 14, 2026. Neumora Therapeutics, Inc. reported in an 8-K filed August 14, 2026 that Joshua Pinto was appointed Chief Executive Officer, effective August 14, 2026. Neumora Therapeutics, Inc. reported in an 8-K filed February 13, 2025 that Joshua Pinto was appointed President, effective February 14, 2025. The proxy statement of Neumora Therapeutics, Inc. reports total compensation of $6,743,238 for Joshua Pinto in fiscal 2025, including a base salary of $645,000. Disclosed compensation is on record for 2 fiscal years. Neumora Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Neumora Therapeutics, Inc. includes Paul L. Berns (CEO, Chairman and Board Member), Michael Milligan (CFO), Bill Aurora (COO) and 7 others.
“on August 12, 2026, the Board also approved the appointment of Dr. Pinto as a Class III director, effective as of the Transition Date, to serve for a term expiring at the 2029 Annual Meeting of Stockholders and until his successor is elected and qualified or until his earlier death, resignation or removal.”
“Joshua Pinto, Ph.D., the Company's current President, will succeed Mr. Berns as the Company's Chief Executive Officer (the "Leadership Transition") effective August 14, 2026 (the "Transition Date").”
Affiliation history
-
Current
2026-08-14–present
-
Current
2026-08-14–present
-
Neumora Therapeutics, Inc. (NMRA)
Proxy statement
CurrentStart not stated–present
Last confirmed April 17, 2026
-
Start not stated–2024-04-25
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Neumora Therapeutics, Inc.
- Paul L. Berns CEO, Chairman, Board Member
- Michael Milligan CFO
- Bill Aurora COO
- Carol Suh COO
- Jason Duncan General Counsel
- Alaa Halawa Board Member
- David Piacquad Board Member
- Kristina Burow Board Member
- Matthew Fust Board Member
- Maykin Ho Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Neumora Therapeutics, Inc. (NMRA) | President | $645,000 | $6,743,238 |
| 2024 | Neumora Therapeutics, Inc. (NMRA) | President | $508,654 | $4,630,573 |